Changes
/* Divesture of certain Animal Health Assets of Wyeth to Boehringer Ingelheim */
Due to this transaction, the Federal Trade Commission approved that it would not harm consumers in any prescription drug market where the companies currently overlap, reduce incentives to innovate, create intellectual property barriers, or allow Pfizer to engage in anticompetitive marketing.
Source: [http://www.ftc.gov/opa/2009/10/pfizer.shtm Source: Federal Trade Commission], [http://www.equinechronicle.com/business/new-pfizer-animal-health-is-unveiled-with-acquisition-of-wyeth.html Equinechronicle]
<br><br>
